Loading
companiesCompany
Nouscom
Nouscom is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens to intercept cancer in Lynch syndrome carriers.
Overview
Nouscom, based in Basel and Rome, is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens, to intercept cancer in people with Lynch syndrome. A phase 1b/2 in Lynch carriers, published in Nature Medicine in March 2026, showed safety and immune responses in most participants, re-treatment and long-term follow-up data were selected for an ESMO 2026 oral, and the vaccine has also been tested with pembrolizumab in microsatellite-instability-high tumours. OnCo links it to colorectal cancer, to off-the-shelf cancer vaccines and chemoprevention, to the MSI-H and neoantigen terms, and to the idea of a randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers. Whether immune responses translate into fewer cancers in carriers is the question only a prevention trial can answer. The off-the-shelf vaccine page carries the field.
Similar pages
- Key paperFirst trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers
Shares A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers, Neoantigen, Off-the-shelf cancer vaccines, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
- IdeaCancer interception vaccines for high-risk carriers
Shares A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers, Off-the-shelf cancer vaccines, Chemoprevention & risk-reducing surgery, Colorectal cancer.
- IdeaA frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval
Shares Neoantigen, Off-the-shelf cancer vaccines, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- PersonVincent K. Tuohy
Shares Off-the-shelf cancer vaccines, Chemoprevention & risk-reducing surgery.
- PersonNina Bhardwaj
Shares Neoantigen, Off-the-shelf cancer vaccines.
- IdeaGet every Lynch syndrome carrier onto the right dose of aspirin
Shares Chemoprevention & risk-reducing surgery, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- Key paperIntegrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability
Shares Neoantigen, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- IdeaVaccinate against the resistance mutation before it takes over
Shares Neoantigen, Off-the-shelf cancer vaccines.